Metabolomic‐based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts
暂无分享,去创建一个
Shelly C. Lu | P. Bedossa | M. Martínez-Chantar | A. Sanyal | J. Crespo | M. Romero-Gómez | R. Brůha | J. Banales | C. Alonso | M. Noureddin | I. Martínez‐Arranz | R. Mayo | J. Mato | J. Caballería | A. Castro | D. D. de Luis | J. Mato | M. Idowu | L. Vítek | R. Jiménez-Agüero | P. Ortiz | R. Aller de la Fuente | J. Stříteský | Itziar Mincholé | A. Martín‐Duce | Mayte Arias | J. M. Mugüerza Huguet | José Ignacio Busteros-Moraza | M. Martínez‐Chantar | M. Romero‐Gomez | A. Martín-Duce | Shelly C. Lu | Arun J. Sanyal | Daniel A. de Luis | Michael O. Idowu
[1] P. Lundberg,et al. Using a 3% Proton Density Fat Fraction as a Cut-Off Value Increases Sensitivity of Detection of Hepatic Steatosis, Based on Results From Histopathology Analysis. , 2017, Gastroenterology.
[2] Shelly C. Lu,et al. Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis. , 2017, Gastroenterology.
[3] R. Goodacre,et al. Metabolomics for the masses: The future of metabolomics in a personalized world , 2017, New horizons in translational medicine.
[4] D. Torres,et al. Nonalcoholic Steatohepatitis and Endpoints in Clinical Trials. , 2016, Gastroenterology & hepatology.
[5] Rohit Loomba,et al. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice. , 2016, Journal of hepatology.
[6] Chris Day,et al. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference , 2016, Alimentary pharmacology & therapeutics.
[7] Z. Goodman,et al. Epidemiology and natural history of non-alcoholic fatty liver disease. , 2016, Metabolism: clinical and experimental.
[8] P. Rodrigues,et al. Circulating microRNAs as Potential Biomarkers in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma , 2016, Journal of clinical medicine.
[9] S. Robson,et al. Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH , 2016, Digestive Diseases and Sciences.
[10] Rohit Loomba,et al. Magnetic resonance elastography is superior to acoustic radiation force impulse for the Diagnosis of fibrosis in patients with biopsy‐proven nonalcoholic fatty liver disease: A prospective study , 2016, Hepatology.
[11] Ibon Martínez-Arranz,et al. Enhancing metabolomics research through data mining. , 2015, Journal of proteomics.
[12] Xiao-dong Guo,et al. Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis , 2015, PloS one.
[13] Robert J. Smith,et al. Fatty liver disease in diabetes mellitus. , 2015, Hepatobiliary surgery and nutrition.
[14] L. Maxim,et al. Screening tests: a review with examples , 2014, Inhalation toxicology.
[15] A. Sanyal,et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis , 2014, Gut.
[16] Rohit Loomba,et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials , 2013, Hepatology.
[17] B. Neuschwander‐Tetri,et al. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients , 2013, Hepatology.
[18] A. Nakajima,et al. [Pathophysiology of NAsh/NAFLD associated with high levels of serum triglycerides]. , 2013, Nihon rinsho. Japanese journal of clinical medicine.
[19] Korbinian Brand,et al. The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. , 2013, Journal of hepatology.
[20] R. Idilman,et al. Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy. , 2013, Radiology.
[21] R. Ehman,et al. Magnetic resonance elastography of liver: Technique, analysis, and clinical applications , 2013, Journal of magnetic resonance imaging : JMRI.
[22] Y. Kawano,et al. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease , 2013, Journal of Gastroenterology.
[23] V. Wong,et al. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. , 2012, Journal of hepatology.
[24] K. Cusi,et al. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.
[25] Shelly C. Lu,et al. Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression. , 2012, Journal of proteome research.
[26] A. Gastaldelli,et al. Diabetes and Nonalcoholic Fatty Liver Disease , 2011, Experimental diabetes research.
[27] L. Gan,et al. Mechanisms and Implications of Age-Related Changes in the Liver: Nonalcoholic Fatty Liver Disease in the Elderly , 2011, Current gerontology and geriatrics research.
[28] Peter Kovacs,et al. Combined proteomic and metabolomic profiling of serum reveals association of the complement system with obesity and identifies novel markers of body fat mass changes. , 2011, Journal of proteome research.
[29] B. Neuschwander‐Tetri,et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings , 2011, Hepatology.
[30] K. Shankar,et al. Lipid fatty acid profile analyses in liver and serum in rats with nonalcoholic steatohepatitis using improved gas chromatography-mass spectrometry methodology. , 2011, Journal of agricultural and food chemistry.
[31] Kevin F Krenitsky,et al. Reduction of novel circulating long-chain fatty acids in colorectal cancer patients is independent of tumor burden and correlates with age , 2010, BMC gastroenterology.
[32] J. H. Lee,et al. Metabolic profiling of plasma in overweight/obese and lean men using ultra performance liquid chromatography and Q-TOF mass spectrometry (UPLC-Q-TOF MS). , 2010, Journal of proteome research.
[33] S. Harrison,et al. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection , 2010, Hepatology.
[34] G. Bedogni,et al. Epidemiology of Non-Alcoholic Fatty Liver Disease , 2010, Digestive Diseases.
[35] Elizabeth M. Brunt,et al. Pathology of nonalcoholic fatty liver disease , 2010, Nature Reviews Gastroenterology &Hepatology.
[36] K. Washington,et al. Assessment of Hepatic Steatosis by Expert Pathologists: The End of a Gold Standard , 2009, Annals of surgery.
[37] S. Harrison,et al. NASH and HCC. , 2009, Clinics in liver disease.
[38] Hirokazu Takahashi,et al. Dysfunctional very‐low‐density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis , 2009, Hepatology.
[39] A. Craxì,et al. Non-alcoholic fatty liver disease pathogenesis: the present and the future. , 2009, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[40] S. Pol,et al. FIB‐4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest , 2007, Hepatology.
[41] Marko Sysi-Aho,et al. Acquired Obesity Is Associated with Changes in the Serum Lipidomic Profile Independent of Genetic Effects – A Monozygotic Twin Study , 2007, PloS one.
[42] O. Cummings,et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.
[43] P. Giral,et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. , 2005, Gastroenterology.
[44] Eric R. Ziegel,et al. An Introduction to Generalized Linear Models , 2002, Technometrics.
[45] H. Cortez‐Pinto,et al. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. , 1999, JAMA.
[46] R. Groszmann,et al. American association for the study of liver diseases , 1992 .
[47] R. Meech,et al. An introduction to generalized linear models , 1990 .
[48] D. Brenner,et al. Magnetic resonance elastography vs. transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease , 2017 .
[49] European Association for the Study of the Liver,et al. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease , 2016, Obesity Facts.
[50] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[51] F. Schaffner,et al. Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.